Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Growth hormone-releasing hormone (GHRH) analogue

CJC-1295 — evidence

What has been published, classified by the kind of document it is. This is not a protocol, not a score, and not a recommendation for use.

Evidence overview

5 records in this file

  • CLINICAL TRIAL2
  • REVIEW1
  • REGULATORY2

Research areas. Anti-doping; Clinical evidence appraisal; Human GH-axis pharmacology; United States compounding.

Publication span. 2006–2026.

What we know

  • Two chemically distinct molecules share the commercial name. Teichman 2006 and Ionescu 2006 studied the DAC form in healthy adults and reported prolonged GH/IGF-1 elevation.
  • No approved drug product exists. FDA's withdrawn-nomination entry does not distinguish DAC from non-DAC.
  • WADA lists GHRH analogues at S2.2.4.

Editorial reading of the records below, labelled as Therapept analysis. How records are built

What remains uncertain

  • Which form a given certificate describes — formula, not the product name, is the identifier.
  • Clinical endpoints beyond GH/IGF-1 biomarkers in healthy adults.

Regulatory notes

No FDA-approved product

  • No approved drug product exists in Drugs@FDA for either form.
  • Listed on FDA's table of bulk substances nominated for compounding and withdrawn by the nominator. FDA's entry does not distinguish between the DAC and non-DAC forms.
  • FDA's published concerns reference serious adverse events reported in association with CJC-1295, including increased heart rate and systemic vasodilatory reaction.

Regulatory status describes how a substance is classified. It is not a safety assessment of any particular material.

Studies and documents

  1. REGULATORY2026Regulatory listing

    FDA table of bulk drug substances nominated for compounding and subsequently withdrawn

    U.S. Food and Drug AdministrationFDA compounding communications

    Objective
    To record FDA's published compounding position.
    Endpoint investigated
    Compounding classification

    Listed on the withdrawn-nominations table. FDA's published concerns reference serious adverse events reported in association with CJC-1295, including increased heart rate and systemic vasodilatory reaction. The entry does not distinguish DAC from non-DAC forms.

    Limitations. FDA's entry does not resolve which chemical form a given commercial product is. Identity still has to be checked by formula on a certificate.

    FDA — Certain bulk drug substances for use in compounding may present significant safety risksReviewed 12 September 2026

  2. REVIEW2026Narrative review

    Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance

    Mendias CL, Awan TMSports Medicine

    Objective
    To place CJC-1295 among unapproved peptides marketed in sports medicine.
    Endpoint investigated
    Published safety/efficacy and regulatory status

    Same 2026 Sports Medicine review, covering CJC-1295 as an unapproved GHRH analogue with animal and limited human pharmacology and no approved indication.

    Limitations. Narrative. Does not replace Teichman/Ionescu primary papers.

    DOI 10.1007/s40279-026-02437-0Mendias and Awan, Sports Med (2026)Reviewed 12 September 2026

  3. REGULATORY2026Anti-doping listing

    WADA Prohibited List — S2.2.4 GHRH analogues

    World Anti-Doping AgencyWADA Prohibited List

    Objective
    To record the 2026 Prohibited List entry.
    Endpoint investigated
    Sporting prohibition status

    Named at S2.2.4 among GHRH analogues. Prohibited at all times; non-Specified.

    Limitations. Anti-doping classification only.

    WADA 2026 Prohibited ListReviewed 12 September 2026

  4. CLINICAL TRIAL2006Randomised, placebo-controlled study in healthy adults

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

    Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LAJournal of Clinical Endocrinology & Metabolism

    Population
    Healthy adults
    Sample
    n = 49 (reported across dose groups in the paper)
    Objective
    To measure the duration of GH and IGF-1 elevation after CJC-1295 with DAC in healthy adults.
    Endpoint investigated
    GH and IGF-1 secretion over days after dosing

    Placebo-controlled study of the DAC form of CJC-1295 in healthy adults, showing prolonged GH and IGF-1 elevation relative to placebo. The molecule studied is the albumin-binding DAC variant, not the non-DAC “Mod GRF 1-29” often sold under the same name.

    Limitations. Healthy adults; hormone biomarkers, not a disease endpoint; DAC form only. Development did not produce an approved drug. A death in a later trial programme is discussed in subsequent reviews as a development event, not as a finding of this paper.

    DOI 10.1210/jc.2005-1536Teichman et al., J Clin Endocrinol Metab (2006) — DAC form of CJC-1295.Reviewed 12 September 2026

  5. CLINICAL TRIAL2006Human physiological study

    Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

    Ionescu M, Frohman LAJournal of Clinical Endocrinology & Metabolism

    Population
    Healthy adults
    Objective
    To test whether GH pulsatility was preserved during prolonged GHRH-receptor stimulation by CJC-1295 with DAC.
    Endpoint investigated
    Pulsatile GH secretion under DAC-CJC-1295

    Companion physiology paper to Teichman 2006, reporting that pulsatile GH secretion persisted during continuous stimulation by the DAC analogue in the conditions studied.

    Limitations. Small physiological study; DAC form; biomarker, not a clinical indication. Does not characterise the non-DAC molecule.

    DOI 10.1210/jc.2006-1702Ionescu and Frohman, J Clin Endocrinol Metab (2006)Reviewed 12 September 2026

Last reviewed 3 September 2026 · Compiled by Therapept Editorial · How these records are built